REIT

Ultime notizie per ALPS Active REIT ETF (NASDAQ:REIT)

ALPS Active REIT ETF

Real Estate

The Fund will, under normal circumstances, seek to achieve its investment objective by investing at least 80% of its net assets in publicly traded equity securities of real estate investment trusts (REITs). The Fund will primarily invest in publicly traded common equity securities of U.S. REITs. The Fund may also invest a portion of its assets in publicly traded common equity of U.S. real estate operating companies (not structured as REITs), publicly traded preferred equity of U.S. REITs and real estate operating companies, and cash and cash equivalents. GSI Capital Advisors LLC, the Funds sub-adviser (GSI Capital or the Sub-Adviser), is responsible for implementing the Funds investment strategy in connection with its active management of the Fund.

Equinix, Inc.

Vici Properties Inc

Public Storage

Welltower Inc.

Simon Property Group Inc

Invitation Homes Inc.

Prologis Inc

LXP Industrial Trust

Healthpeak Properties Inc

Equity Residential

Reit 1 Ltd

Reitar Logtech Holdings Limited - Ordinary shares

Reitar Logtech Holdings Ltd

REITMANS CANADA LTD A by Reitmans (Canada) Limited

Reitmans (Canada) Ltd

REITMANS CDA LTD by Reitmans (Canada) Limited

HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) underwent analysis by 29 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">16</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $863.14, along with a high estimate of $980.00 and a low estimate of $725.00. This current average reflects an increase of 14.0% from the previous average price target of $757.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1739480475_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of HubSpot among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$900.00</td>
<td>$825.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$885.00</td>
<td>$690.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$980.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$783.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$825.00</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$900.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$850.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$920.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$940.00</td>
<td>$835.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$925.00</td>
<td>$880.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$775.00</td>
<td>$740.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$815.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$898.00</td>
<td>$835.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$710.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$808.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$725.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Drew Foster</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$835.00</td>
<td>$810.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$860.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$725.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$835.00</td>
<td>$747.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$825.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$810.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$825.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$850.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$775.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$880.00</td>
<td>$750.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HubSpot. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of HubSpot compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of HubSpot's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of HubSpot's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUBS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on HubSpot analyst ratings.</a>
<h2>Delving into HubSpot's Background</h2>
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
<h3>Financial Insights: HubSpot</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: HubSpot displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.12%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: HubSpot's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 1.22%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): HubSpot's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.49%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): HubSpot's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.24%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: HubSpot's debt-to-equity ratio is below the industry average at 0.43, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

HUBS

A Glimpse Into The Expert Outlook On HubSpot Through 29 Analysts

During the last three months, 11 analysts shared their evaluations of CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $69.55, a high estimate of $80.00, and a low estimate of $60.00. This current average has increased by 5.09% from the previous average price target of $66.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1739480467_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of CVS Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for CVS Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CVS Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CVS Health analyst ratings.</a>
<h2>Get to Know CVS Health Better</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>CVS Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: CVS Health displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 6.31%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.09%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): CVS Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.12%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: CVS Health's debt-to-equity ratio is below the industry average. With a ratio of 1.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 11 Analysts Discuss CVS Health Stock

Throughout the last three months, 10 analysts have evaluated Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $129.0, a high estimate of $140.00, and a low estimate of $119.00. This upward trend is apparent, with the current average reflecting a 0.16% increase from the previous average price target of $128.80.
<img src="https://www.benzinga.com/files/images/story/2025/1739480453_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Blueprint Medicines by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$129.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$119.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blueprint Medicines. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Blueprint Medicines's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Blueprint Medicines's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>Get to Know Blueprint Medicines Better</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>A Deep Dive into Blueprint Medicines's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Blueprint Medicines's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 126.61% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -43.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Blueprint Medicines's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -17.77%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Blueprint Medicines's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Blueprint Medicines's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.51, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPMC

Breaking Down Blueprint Medicines: 10 Analysts Share Their Views

In the latest quarter, 14 analysts provided ratings for Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $1074.57, a high estimate of $1200.00, and a low estimate of $822.00. Witnessing a positive shift, the current average has risen by 4.48% from the previous average price target of $1028.46.
<img src="https://www.benzinga.com/files/images/story/2025/1739480446_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Equinix by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$1033.00</td>
<td>$1114.00</td>
</tr>
<tr>
<td>Ari Klein</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1065.00</td>
<td>$1085.00</td>
</tr>
<tr>
<td>Timothy Horan</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$975.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1065.00</td>
<td>$1075.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$1200.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$1200.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1075.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$1200.00</td>
<td>-</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$1114.00</td>
<td>$985.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1025.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1100.00</td>
<td>$985.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$1090.00</td>
<td>$935.00</td>
</tr>
<tr>
<td>Erik Rasmussen</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$1080.00</td>
<td>$995.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$822.00</td>
<td>$810.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Equinix. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Equinix compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Equinix's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EQIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Equinix analyst ratings.</a>
<h2>About Equinix</h2>
Equinix operates 260 data centers in 71 markets worldwide. It generates 44% of total revenue in the Americas, 35% in Europe, the Middle East, and Africa, and 21% in Asia-Pacific. The firm has more than 10,000 customers, including 2,100 network providers, that are dispersed over five verticals: cloud and IT services, content providers, network and mobile services, financial services, and enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from interconnection. Equinix operates as a real estate investment trust.
<h3>Unraveling the Financial Story of Equinix</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Equinix's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.79%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 13.49%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Equinix's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Equinix's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.87%, the company showcases efficient use of assets and strong financial health.
Debt Management: Equinix's debt-to-equity ratio is below the industry average at 1.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EQIX

Equinix Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)

Leonardo DRS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRS#NASDAQ">DRS</a>) announced today that it was awarded a contract to provide and integrate the latest Battle Management Systems (BMS) C4I hardware and software into new Royal Thailand Army combat vehicles. The total value of the award is more than $7 million. The contract was awarded by the U.S. Army through the U.S. Government Grant Assistance program.
Under the contract Leonardo DRS will provide its ruggedized C4I Battle Management System (BMS) hardware and is the lead integrator for the technology. The work includes integrating BMS software, cyber protection, network integration, training, and sustainment capability for newly acquired Stryker vehicles in the Royal Thailand Army. Leonardo DRS will be supported by a local Thai defense company, Chaiseri Defense, for the installation, training, and in-country support for this program.

News

Contracts

Leonardo DRS Awarded ~$7M Contract To Integrate Critical C4I Capabilities Into New Royal Thailand Army Stryker Vehicles

During the last three months, 10 analysts shared their evaluations of Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $113.3, a high estimate of $126.00, and a low estimate of $99.00. Surpassing the previous average price target of $104.44, the current average has increased by 8.48%.
<img src="https://www.benzinga.com/files/images/story/2025/1739480429_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Q2 Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Sklar</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Andrew Schmidt</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jon Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$126.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Q2 Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Q2 Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Q2 Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Q2 Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/QTWO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Q2 Holdings analyst ratings.</a>
<h2>Delving into Q2 Holdings's Background</h2>
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
<h3>A Deep Dive into Q2 Holdings's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Q2 Holdings displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 12.94%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Q2 Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.74% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Q2 Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.42%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.94%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Q2 Holdings's debt-to-equity ratio surpasses industry norms, standing at 1.09. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

QTWO

A Glimpse Into The Expert Outlook On Q2 Holdings Through 10 Analysts

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $42.5, a high estimate of $45.00, and a low estimate of $40.00. Experiencing a 5.56% decline, the current average is now lower than the previous average price target of $45.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739480412_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Rexford Industrial Realty is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$41.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rexford Industrial Realty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rexford Industrial Realty compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Rexford Industrial Realty's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Rexford Industrial Realty's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REXR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rexford Industrial Realty analyst ratings.</a>
<h2>Unveiling the Story Behind Rexford Industrial Realty</h2>
Rexford Industrial Realty Inc is a real estate investment trust engaged in the acquisition, ownership, and operation of industrial properties in Southern California. The company mainly focuses on leasing facilities in infill markets or relatively wealthy urban areas with a general scarcity of developable land. The vast majority of Rexford's real estate portfolio, in terms of square footage, revenue generation, and total value, comprises light manufacturing and distribution warehouse buildings located in Los Angeles and San Diego. The company's tenants are firms in the wholesale and retail, light manufacturing, industrial equipment, and food and beverage industries.
<h3>A Deep Dive into Rexford Industrial Realty's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Rexford Industrial Realty showcased positive performance, achieving a revenue growth rate of 17.74% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Rexford Industrial Realty's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.82%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Rexford Industrial Realty's ROA excels beyond industry benchmarks, reaching 0.52%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.42.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REXR

Rexford Industrial Realty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<a href="https://register.epo.org/application?number=EP16762527">https://register.epo.org/application?number=EP16762527</a>
<figure class="image"><img src="https://pbs.twimg.com/media/GjshQSmawAAD8sU?format=jpg&amp;name=small" alt="Image" /></figure>

Biotech

General

PAVM

PAVmed Has Received A Decision To Grant European Patent Number EP3267955 Titled "CONTINUOUS FLOW BALLOON CATHETER SYSTEMS AND METHODS OF USE (FOR INFUSION OR ABLATION OF TARGET TISSUES)"

Macro Economic Events

Global

Economics

Trump Says Officials From U.S., Russia To Meet In Munich On Friday, Ukraine Also Invited

New trademarks filed by Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) could indicate what the company has planned for a 20-person vehicle it showed <a href="https://www.benzinga.com/news/24/10/41284847/tesla-reveals-two-seater-cybercab-that-drives-itself">off in October.</a>
What Happened: Benzinga previously reported that Tesla <a href="https://www.benzinga.com/news/24/10/41342914/cybercab-or-robotaxi-robovan-or-robobus-tesla-trademark-filings-might-reveal-elon-musks-preferred-na">filed a trademark </a>for Robobus for the large vehicle that was being referenced as Robovan.
New trademark <a href="https://tsdr.uspto.gov/#caseNumber=99032883&amp;caseSearchType=US_APPLICATION&amp;caseType=DEFAULT&amp;searchType=statusSearch">filings </a>unveiled by <a href="https://carmoses.com/tesla-robus-the-future-of-autonomous-transportation/">CarMoses </a>show Tesla is also considering the phrase "Robus" for the vehicle.
With both Robus and Robous trademarked by Tesla now, it seems more likely that the electric vehicle company will use some form of combining the words robot and bus to create the new name for the vehicle.
The trademarks cover several potential use cases, including electric buses and ridesharing services, as reported by <a href="https://insideevs.com/news/750473/tesla-robus-trademark-robotaxi-robovan/">InsideEVs</a>. The trademarks mention peer-to-peer vehicle sharing, time-based ridesharing services and temporary use of vehicles according to the report.
Benzinga reached out to Tesla for comment and did not hear back.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: Robotaxis are a big part of Tesla&#8217;s future growth plans. The company highlighted its robotaxis, also known as Cybercars, during the October 2024 event.
The unveiling of the Robovan, or whatever name it will go by, was more of a surprise for guests at the event.
Robus could be a trademark that covers all of the company robotaxi vehicles including the robotaxi/cybercar and the robovan/robobus.
The launch of the Robus ridesharing service could put more pressure on Uber and Lyft if Tesla is able to get its self-driving vehicles tested on roads and approved for use.
Trademarks filed don't guarantee they will be granted or that the company will use the names. In this case, the trademark filings could point to items that could be years away from being launched by Tesla, if at all.
TSLA Price Action: Tesla stock is up 4.3% to $350.85 on Thursday versus a 52-week trading range of $138.80 to $488.54. Tesla stock is down 7.4% year-to-date in 2025 and up over 90% in the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43321103/tesla-q4-earnings-highlights-revenue-miss-eps-miss-ev-updates-automaker-says-2025-will-be-a-seminal-year">Tesla Q4 Earnings Highlights: Revenue Miss, EPS Miss, EV Updates, Automaker Says &#8216;2025 Will Be A Seminal Year&#8217;</a></li>
</ul>
Photo: Shutterstock

Tech

TSLA

Tesla Registers 'Robus,' 'Robobus,' Hinting At Ride-Share, Transit Vision

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has outperformed the market over the past 5 years by 2.28% on an annualized basis producing an average annual return of 14.88%. Currently, Uber Technologies has a market capitalization of $169.26 billion. 
Buying $1000 In UBER: If an investor had bought $1000 of UBER stock 5 years ago, it would be worth $2,000.50 today based on a price of $80.38 for UBER at the time of writing.
<h3>Uber Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739479509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

UBER

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

In the current session, the stock is trading at $109.68, after a 0.36% increase. Over the past month, Brown &amp; Brown Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) stock increased by 4.43%, and in the past year, by 33.80%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1739479509_0_0.png" alt="Past Year Chart" />

<h3>Brown &amp; Brown P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 54.29 in the Insurance industry, Brown &amp; Brown Inc. has a lower P/E ratio of 31.59. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1739479509_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Brown & Brown Inc's Price Over Earnings

WIIM

SYRA

Syra Health shares are trading higher after the company announced it was awarded a six-month $135,000 healthcare training contract

Cryptocurrency markets are trading lower on Thursday, continuing to trade in a tight range.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$95,842.60</td>
<td>-1.3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,648.21</td>
<td>-1%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$193.46</td>
<td>+0.07%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.46</td>
<td>+0.8%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2571&nbsp;&nbsp;</td>
<td>-1.5%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001617</td>
<td>-3.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 4.9% and daily active addresses higher by 8.5%. Transactions greater than $100,000 are down from 10,487 to 9,846 in a single day. Exchanges netflows are down by 134.4%.</li>
<li>Coinglass data reports 107,479 traders were liquidated in the past 24 hours for $202.63 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43699338/opensea-launches-os2-platform-with-token-trading-and-sea-community-token">OpenSea Launches OS2 Platform With Token Trading And $SEA Community Token</a></li>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43702814/bitcoin-mining-equipment-seized-at-us-ports-nationwide-report">Bitcoin Mining Equipment Seized At US Ports Nationwide: Report</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43707177/matterfi-wallet-technology-to-integrate-with-trrue-blockchain-ecosystem">MatterFi Wallet Technology To Integrate With Trrue Blockchain Ecosystem</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43683304/nasdaq-listed-crypto-exchange-coincheck-reports-loss-of-98-million-in-q3-shares-tumble-7">Nasdaq-Listed Crypto Exchange Coincheck Reports Loss Of $98 Million In Q3, Shares Tumble 7%</a></li>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43674050/us-releases-russian-bitcoin-exchange-co-founder-alexander-vinnik-in-prisoner-deal-with-moscow">US Releases Russian Bitcoin Exchange Co-Founder Alexander Vinnik In Prisoner Deal With Moscow</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>TRUMP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>)</td>
<td>&nbsp;$16.57</td>
<td>+9.3%</td>
</tr>
<tr>
<td>Kaspa (CRYPTO: KAS)</td>
<td>&nbsp;$0.1048</td>
<td>+8.5%</td>
</tr>
<tr>
<td>Jito (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">JTO</a>)</td>
<td>&nbsp;$3.04</td>
<td>+6.7%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Ali Martinez believes Bitcoin's true direction won&#8217;t be clear until it breaks out of its current range. 
The market is in a holding pattern, and price movements will reveal the next move once the breakout occurs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We won&#39;t know the real direction of the trend until <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> breaks out of this range! <a href="https://t.co/t82RWjMz6i">pic.twitter.com/t82RWjMz6i</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1890111950820200939?ref_src=twsrc%5Etfw">February 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1890083766112076080">pointed</a> out that Bitcoin is in the red for February, marking only the third time in history if this trend continues through the month. 
He also mentioned that March tends to be volatile, with both significant gains and steep declines, suggesting that large price swings are expected.
CryptoCon <a href="https://x.com/CryptoCon_/status/1890120187988328530">noted</a> that the current Bitcoin cycle has been more methodical and healthier compared to past cycles, avoiding the extreme volatility seen in earlier runs. 
He believes that a mix of fear and boredom could be beneficial for a sustained bull market. So far, there have only been two short periods of &#8220;Extreme Greed,&#8221; leaving ample room for further growth.
Axel Adel Jr highlighted that Bitcoin's 1-week realized volatility has dropped to 8.7%. If conditions don't improve, the next move could see a drop to $92,000.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f6a8;The 1-week realized volatility has dropped to 8.7%. Weak liquidity is a warning sign. The price is near the 111DMA. If conditions do not improve, the next move could be a drop to $92K, below the 111DMA. <a href="https://t.co/uPntn19Ob7">pic.twitter.com/uPntn19Ob7</a>
&mdash; Axel &#x1f48e;&#x1f64c; Adler Jr (@AxelAdlerJr) <a href="https://twitter.com/AxelAdlerJr/status/1890123340897239537?ref_src=twsrc%5Etfw">February 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43706856/could-inflation-unemployment-derail-the-bitcoin-bull-run">Could Inflation, Unemployment Derail The Bitcoin Bull Run?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$JTO

$KAS

$SHIB

$SOL

$TRUMP

$XRP

Bitcoin, Ethereum, Dogecoin Dip As XRP Holds Steady: Trader Warns Of Potential Drop To $92,000 Without Improvement

CDRO

Codere Online shares are trading higher after the company announced it received a listing extension from the Nasdaq

<img alt="Inflation " class="article-image-one" src="https://www.marketbeat.com/logos/articles/med_20250212093020_inflation-persists-but-so-do-stock-opportunities-r.jpg" style="height:720px; width:1200px" />
The&nbsp;<a href="https://www.bls.gov/cpi/">January CPI</a> report was hot, much hotter than expected, and raised the risk of FOMC tightness. Not just higher-for-longer near current levels but a reduced chance for even a single 25 basis rate cut in 2025 and a growing possibility hike will be back on the table. This increases the odds of a Fed-induced recession, but opportunities for investors persist. Inflation is a hot problem but, so far, has yet to impact economic activity or the uptrend in stocks.&nbsp;
<a href="https://www.marketbeat.com/market-data/">Economic activity</a> remains solid, with Q1 GDP forecast to run near 3.0% in Q1. What this means for investors is continued stock market growth and a high likelihood that the uptrend in the <a href="https://www.marketbeat.com/stocks/NYSEARCA/SPY/">S&amp;P 500 (NYSEARCA: SPY)</a> will continue. The market pulled back following the CPI release and may deepen the move before the rebound begins, but a rebound is the most likely outcome; the CPI-induced dip is a buying opportunity.&nbsp;
<h2>Labor Market Health, Earnings Growth, and Capital Returns Support S&amp;P 500 Uptrend</h2>
Labor market strength is one reason the CPI report is less of a selling event than some would think. The January labor data included significant annual revisions but <a href="https://www.marketbeat.com/stock-ideas/what-pmi-data-says-about-the-nfp-report-3-hidden-opportunities/">aligned with the trends</a>. The trends include steady job creation, employment growth accelerating at year&#39;s end, low unemployment, and rising wages. Wages grew at a 4%+ pace, a critical factor for inflation and the consumer outlook, underpinning inflation yet sustaining consumer health. According to the CPI, inflation is up 3.0% and 3.3% at the headline and core levels, leaving the &quot;average consumer&quot; stronger than a year ago despite the higher prices.&nbsp;
S&amp;P 500 earnings growth is also a factor in why the index can rally higher. The decreased chances for lower rates will impact the outlook, but growth is expected, nonetheless. As it is, the consensus figures assume steady growth in Q12025 relative to 2024 and sequential acceleration throughout the year. The difference is that&nbsp;<a href="https://www.marketbeat.com/stocks/sectors/">all sectors</a> will produce growth, compared to only nine in 2024, with six growing by more than 10% and leaders including technology, healthcare, and industrials. In 2026, those trends are expected to continue and produce another year of mid-teens earnings growth.&nbsp;
Earnings are critical on their own but more so because of the impact on capital returns. The S&amp;P 500 companies will increase dividends and buybacks on average by high-single and low-double-digit amounts in 2025 and sustain the trend in 2026. That means a dwindling share count compounded by business growth, dividend distribution, and balance sheet improvements, which are a strong tailwind for shareholder value.&nbsp;
<h2>The Risk is Inflation; It is Accelerating</h2>
The risk is inflation. The January data is hot and shows acceleration contrary to the expected contraction. Inflation can continue to accelerate in this scenario because the Fed&#39;s policy may be too lenient, and Trump&#39;s policies are expected to be inflationary. On the one hand,&nbsp;<a href="https://www.marketbeat.com/stock-ideas/do-new-tariffs-signal-rising-inflation-a-technical-breakdown/">tariffs may impact prices</a>, while on the other, easing business headwinds are expected to drive expansion and labor investment.
The market reacted to the news as expected, with the S&amp;P 500 declining immediately after the release. However, traders seized the early morning sell-off as an opportunity, showing their support at the 30-day EMA. If this level continues to be supported, the market could quickly rebound and move up to set new highs. If not, the S&amp;P 500 could move to the 5,960 to 5,790 level, where support is firmer. In that scenario, the market could remain range-bound until later in the year.&nbsp;
<img alt="" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20250212092112_chart-spy-2122025.png" style="height:427px; width:916px" />
<h2><a href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink" style="text-decoration:none;color:var(--dark-blue); font-weight:500;">Where Should You Invest $1,000 Right Now?</a></h2>
Before you make your next trade, you&#39;ll want to hear this.
MarketBeat keeps track of Wall Street&#39;s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the <a href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink">five stocks</a> that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
<a class="btn btn-featured" href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink" style="text-decoration:none">See The Five Stocks Here </a>
The article &quot;<a href="https://www.marketbeat.com/originals/inflation-persists-but-so-do-stock-opportunities-rally-on/">Inflation Persists, But So Do Stock Opportunities: Rally On</a>&quot; first appeared on MarketBeat.

Broad U.S. Equity ETFs

ETFs

Inflation Persists, But So Do Stock Opportunities: Rally On

LYEL

Johnson & Johnson 13F Shows New Stake In Lyell Immunopharma

Legal

Transportation Secretary Says He Has Requested That Boeing CEO Come To DC As Soon Possible

Thousands of Americans living abroad woke up to something they weren&#8217;t expecting this month – their Social Security benefits had been suspended. The reason? They didn't submit a required document called the Foreign Enforcement Questionnaire. The Social Security Administration (SSA) uses this form, sent out annually or biannually, to verify that recipients outside the U.S. are still eligible for payments.
<h2 class="wp-block-heading">Who Is Affected?</h2>
The SSA has confirmed that suspensions impact those receiving Social Security benefits while living outside the U.S. <a href="https://bb.usembassy.gov/social-security-update/">Notices</a> have already gone out to beneficiaries in Mexico, Barbados, Costa Rica, Haiti and other countries.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Not every American living abroad has to worry, though. You do not need to submit the form if you are under 90 years old, currently receiving benefits, and your Social Security Number ends in 50-99. You will receive one between June and July 2025. Additionally, if your official address on record is in the United States, you can ignore this notice.
<h2 class="wp-block-heading">How to Reinstate Your Benefits</h2>
If your February payment didn't arrive, your benefits have likely been suspended. Payments for this month started going out on Jan. 31, with the last ones issued by Feb. 28. You need to take action immediately to get your payments reinstated.
Submit the required Foreign Enforcement Questionnaire (SSA-7162 if receiving payments directly, SSA-7161 if you have a representative payee) or contact the Federal Benefits Unit (FBU) for your country. Once your form is received and processed, your benefits should be reinstated within seven business days.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
<h2 class="wp-block-heading">This Suspension Is Not Related to DOGE or Elon Musk</h2>
While <a href="https://www.benzinga.com/personal-finance/24/11/42217382/bernie-sanders-demands-scrap-the-cap-on-social-security-taxes-its-absurd-a-billionaire-pays-same-amount-as-middle-class-earners">Social Security funding</a> has been a hot topic in Washington, these recent suspensions are unrelated to the controversy surrounding Elon Musk and the Department of Government Efficiency (DOGE).
Musk and DOGE have faced backlash after a judge <a href="https://www.benzinga.com/news/25/02/43578729/court-halts-musks-doge-squad-from-gaining-access-to-treasury-payment-systems-a-risk-of-irreparable-harm">temporarily blocked them</a> from accessing the Treasury Department's payment system, which handles Social Security payments, tax refunds and federal salaries. This move came after concerns that DOGE had <a href="https://www.benzinga.com/25/02/43549516/elon-musk-led-doges-marko-elez-who-had-treasury-payment-access-resigns-over-racist-social-media-posts">accessed sensitive information</a>, such as Social Security numbers and bank account details. Treasury officials later clarified that DOGE had only "read-only" access, but Democrats have raised alarms about possible government overreach.
Despite the political storm in Washington, the current suspension of Social Security benefits for Americans abroad is entirely unrelated to DOGE, Musk or any policy changes under President Donald Trump. This is a routine SSA process to verify eligibility, and anyone who submits their required form will have their payments reinstated.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
<h2 class="wp-block-heading">What To Do Next</h2>
If you live abroad and rely on Social Security benefits, check whether you have received the Foreign Enforcement Questionnaire. If not, contact your Federal Benefits Unit (FBU) immediately to avoid further delays.
The SSA has been sending out these forms for decades, but this unexpected hold on payments has been a frustrating wake-up call for many affected beneficiaries. Fortunately, the solution is straightforward – send in the form, follow up with the FBU and your benefits should resume within a week.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

'Your Benefits Have Been Suspended' – Some Americans Abroad Suddenly Lose Access To Their Social Security Benefits

Southern's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) short percent of float has fallen 5.23% since its last report. The company recently reported that it has 17.88 million shares sold short, which is 1.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Southern Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739478624_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Southern has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Southern's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Southern's peer group average for short interest as a percentage of float is 2.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Southern's Recent Short Interest

New Home Market Cap Points To Disappointing Year

Pending Home Sales Unexpectedly Fall For First Time In 5 Months

U.S. Housing Market: Home Price Gains Accelerated In November 2024

Data center REITs drive real estate stocks down, earnings fail to impress

Volatility Is Back

Q4 2024 Economic Update

What We're Watching This REIT Earnings Season

Healthpeak prices offering of 5.375% senior unsecured notes due 2035

Real estate stocks end in green when broader markets suffer the impact of trade war concerns

Real estate stocks end in green despite broader markets close lower on trade concerns

Comments

ALPS Active REIT ETF

Notizie

Ultime notizie per ALPS Active REIT ETF (NASDAQ:REIT)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO